OLMA · Olema Pharmaceuticals, Inc.
$11.59
+0.24 (+2.11%)
At close · Jul 21
Going-concern doubt
— flagged May 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“We have incurred net losses since inception, and we expect to continue to incur net losses for the foreseeable future. In addition, we may be unable to continue as a going concern over the long term.”View the 10-Q filed May 12, 2026
Market Cap
$1.01B
Shares
87.35M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$162.45M
-25.5%
FY2025
Diluted EPS
-$1.87
+15%
FY2025
Operating Cash Flow
-$146.72M
-40.6%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| $176.31M | $157.7M | $124.52M | $86.14M | $82.27M | $51.1M | |
| $25.51M | $21M | $17.74M | $18.82M | $24.71M | $20.39M | |
| — | $490K | $393K | $377K | $357K | $163K | |
| $201.81M | $178.7M | $142.26M | $104.96M | $106.99M | $71.49M | |
| -$201.81M | -$178.7M | -$142.26M | -$104.96M | -$106.99M | -$71.49M | |
| — | — | — | — | — | $653K | |
| $16.48M | $16.22M | $12.68M | $8.33M | $2.23M | $442K | |
| $16.66M | $16.25M | $12.78M | $8.31M | $2.2M | $395K | |
| — | -$162.45M | — | — | — | — | |
| — | $3000 | $2000 | $2000 | $1000 | — | |
| -$185.15M | -$162.45M | -$129.47M | -$96.66M | -$104.79M | -$71.1M | |
| — | — | — | — | — | -$71.1M | |
| -$186.03M | -$161.97M | -$129.68M | -$94.5M | -$106.45M | -$71.25M | |
| USD/shares | — | -$1.87 | -$2.20 | -$2.14 | -$2.62 | -$1.80 |
| USD/shares | — | -$1.87 | -$2.20 | -$2.14 | -$2.62 | -$1.80 |
| shares | — | 87.01M | 58.74M | 45.25M | 40M | 39.52M |
| shares | — | 87.01M | 58.74M | 45.25M | 40M | 39.52M |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.46×
EV/EBIT
—
Biotechnology median 26.45×
P/E (TTM)
—
Biotechnology median 7.03×
Key facts
CIK
1750284
CUSIP
68062P106
13F (30d)
13 filings
13 filers
Visit website
Investor relations